Alsheikh-Ali, A., Lin, J., Abourjaily, P., Ahearn, D., Kuvin, J. and Karas, R. ( 2007) Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol100: 1499-1501.
2.
Cannon, C., Braunwald, E., McCabe, C., Rader, D., Roulieau, J., Belder, R. et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med350: 1495-1504.
3.
Davidson, M., Stein, E., Bays, H., Maki, K., Doyle, R., Schalwitz, R. et al. (2007) Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther19: 1354-1367.
4.
FIELD Study Investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366: 1849-1861.
5.
Ginsberg, H., Elam, M., Lovato, L., Crouse III, J., Leiter, L., Linz, P. et al.; ACCORD Study Group (2010 ) Effects of combination lipid therapy in type 2 diabetes mellitus . N Engl J Med362: 1563-1574.
6.
Greenstein, A., Tavakoli, M., Mojaddidi, M., Al-Sunni, A., Matfin, G. and Malik, R.A. ( 2007) Microvascular complications: evaluation and monitoring relevance to clinical practice, clinical trials, and drug development. Brit J Diabetes Vascular Dis7: 166-171.
7.
Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.S., Eckel, R.H., Frankliet, B.A. et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation112: 2735-2752.
8.
Keech, A., Mitchell, P., Summanen, P., O’Day, J.U., Davis, T., Moffitt, M. et al. (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (the FIELD study): a randomised controlled trial. Lancet370: 1687-1697.
9.
LaRosa, J., Grundy, S., Waters, D., Shear, C., Barter, P., Fruchart, J. et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med352: 1425-1435.
10.
Leiter, L., Feely, J., Ferrieres, J.A., Gitt, A., Gonzalez-Juanatey, J., Korsgaared Thomsen, K. et al. (2009) Characteristics of statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidemia International Study. World Diabetes Congress, Montreal: Canada, (Abstract D-0812).
11.
National Institute for Health and Clinical Excellence ( 2010) Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG 67), http://www.nice.org.uk/CG067 (accessed 25 May 2010).
12.
Robins, S.J., Collins, D., Wittes, J.T., Papademetriou, V., Deedwania, P.C., Schaefer, E.J. et al. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. J Am Med Assoc285: 1585-1591.
13.
Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.K. et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J28: 88-136.
